Standard-of-Care Therapy for Metastatic Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Metastatic Cancer+1 MoreStandard-of-Care Therapy - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether targeted therapy based on a tumor's genetic profile is more effective than standard treatment for metastatic cancer.

Eligible Conditions
  • Metastatic Cancer
  • Recurrent Malignant Neoplasm

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Continuous Monitoring, expected range from 2 months to 3 years

Year 3
Comparison of Progression-Free Survival (PFS) Between the Two Randomized Arms

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Arm A: Targeted Therapy
1 of 2
Arm B: Standard-of-Care Therapy
1 of 2

Active Control

Experimental Treatment

1362 Total Participants · 2 Treatment Groups

Primary Treatment: Standard-of-Care Therapy · No Placebo Group · N/A

Arm B: Standard-of-Care Therapy
Drug
Experimental Group · 1 Intervention: Standard-of-Care Therapy · Intervention Types: Drug
Arm A: Targeted Therapy
Drug
ActiveComparator Group · 1 Intervention: Targeted Therapy Based on Molecular Profiling · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: continuous monitoring, expected range from 2 months to 3 years

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,789,017 Total Patients Enrolled
Tempus LabsIndustry Sponsor
10 Previous Clinical Trials
4,318 Total Patients Enrolled
Apostolia M TsimberidouPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
36 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The patient has biopsy-accessible tumor; for patients who had no prior anticancer therapy and had surgical resection within a year and tumor tissue is immediately available, that tumor will be analyzed and no biopsy will be needed.
You have measurable disease.\n
You have a performance status of 0-1.
You have a platelet count of at least 100,000/ul.
You have a total bilirubin level of 1.5 x the ULN or less.